Matthew S. McIlwain, Director at Nautilus Biotechnology, Inc. (NAUT), bought 73,940 shares at $7.68 ($570K) on 2021-08-24, disclosed to the SEC on 2021-08-26.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.68 | 13,568 | $104K | 18.3% |
| 2 | $7.68 | 13,568 | $104K | 18.3% |
| 3 | $7.74 | 11,693 | $91K | 15.9% |
| 4 | $7.74 | 11,693 | $91K | 15.9% |
| 5 | $7.71 | 11,709 | $90K | 15.8% |
| 6 | $7.71 | 11,709 |
| $90K |
| 15.8% |
| Total | $7.71 avg | 73,940 | $570K | 100% |
| Filing → |
| NAUT | BUY | 2021-11-17 | $530K | — | Filing → |
| SMAR | SELL | 2020-12-14 | $4.8M | — | Filing → |
| SMAR | SELL | 2020-06-25 | $2.6M | — | Filing → |